Mostrar el registro sencillo

dc.contributor.authorSánchez Castañón, María
dc.contributor.authorGómez C.
dc.contributor.authorHeras Castaño, Gonzalo de las
dc.contributor.authorLópez Hoyos, Marcos 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-03-11T11:04:01Z
dc.date.available2024-03-11T11:04:01Z
dc.date.issued2012
dc.identifier.issn2038-0305
dc.identifier.issn2038-3274
dc.identifier.urihttps://hdl.handle.net/10902/32172
dc.description.abstractPurpose: To investigate the utility of different combinations of serum anti-carbonic anhydrase II antibodies (CA II Abs), anti-α amylase antibodies (AMY-α Abs) and IgG4 levels for the diagnosis of autoimmune pancreatitis (AIP). Methods: We recruited 93 patients with clinical suspicion for AIP and 94 patients as control groups between June 2003 and October 2009. Serum antibodies were measured using homemade enzyme linked immunosorbent assay and IgG4 levels were determined by nephelometry. Results: Both CA-II Abs and AMY-α Abs had the highest sensitivity (83%) although AMY-α Abs (89%) were more specific than CA-II Abs (75%). The presence of increased IgG4 levels was the most specific serological marker (94%), but it had the lowest sensitivity (58%). The combination of the three serological markers altogether had the highest specificity (99%) and positive predictive value (PPV) (86%), but they had a rather low sensitivity (50%). When we combined CA-II Abs and AMY-α Abs without IgG4 levels, we got the highest sensitivity (75%) and negative predictive value (98%) but the specificity and the PPV decreased to 93 and 50%, respectively. Importantly, AMY-α Abs were not detected in pancreas cancer. Conclusions: The presence of serum CA-II and AMY-α Abs with increased IgG4 is useful in the differential diagnosis of AIP from pancreatic cancer.es_ES
dc.format.extent7 p.es_ES
dc.language.isoenges_ES
dc.publisherBMC (part of Springer Nature)es_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceAuto-Immunity Highlights, 2012, 3(1), 11-17es_ES
dc.subject.otherAutoimmune pancreatitises_ES
dc.subject.otherAnti-a amylase antibodieses_ES
dc.subject.otherAnti-carbonic anhydrase II antibodieses_ES
dc.subject.otherPancreatic canceres_ES
dc.subject.otherDiagnosises_ES
dc.subject.otherIgG4es_ES
dc.titleDifferentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1007/s13317-011-0024-x
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International